Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1138 articles about Moderna, Inc.
-
Moderna released positive interim Phase I data from its clinical trial of mRNA-1273, its mRNA vaccine against SARS-CoV-2.
-
Clinical Catch-Up: May 11-15
5/18/2020
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
-
Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House’s Operation Warp Speed Initiative
5/15/2020
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that Dr. Moncef Slaoui has resigned from Moderna’s Board of Directors upon appointment of his new role to oversee the White House’s Operation Warp Speed initiative.
-
The designation will expedite regulatory review of the medication should it prove to be safe and effective.
-
Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
5/12/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
-
Clinical Catch-Up: May 4-8
5/11/2020
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look. -
Moderna to Present at Upcoming Investor Conferences in May 2020
5/8/2020
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in upcoming investor conferences
-
One day after Moderna announced its COVID-19 vaccine candidate has moved into Phase II testing, Chief Executive Officer Stéphane Bancel laid out the bad news – if it works, there won’t be enough of the vaccine to be quickly distributed across the globe.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
-
Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates
5/7/2020
Progress on novel coronavirus vaccine (mRNA-1273) includes FDA clearance to proceed with Phase 2 study Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020 Awarded up to $483 million funding from BARDA for accelerated development of mRNA-1273 Entered strategic collaboration with Lonza Ltd. to manufacture up to one billion doses of mRNA-1273 per year Up to $2.4 billion to invest, including cas
-
Stéphane Bancel, Moderna’s chief executive officer, said the Phase II study is a crucial step in advancing the vaccine candidate as the company looks toward the goal of moving into Phase III.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
-
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
5/1/2020
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine against the novel coronavirus and additional Moderna products in the future.
-
As the situation progresses, they hope to establish more production suites across Lonza’s facilities globally, with a goal of manufacturing up to 1 billion doses of mRNA-1273 per year at the currently expected dose of 50 µg.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
-
Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
4/27/2020
600 participant Phase 2 study to begin upon IND acceptance and safety data from ongoing NIH-led Phase 1 study
-
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.